Form 4 for RNAZ Transcode Therapeutics, Inc.
Accepted 2023-10-02 00:00:00 ET · period of report 2023-09-28 · accession 0001104659-23-105924 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-02 | 2023-09-28 | RNAZ | Dudley Robert Michael | CEO, Dir | P - Purchase | $0.51 | +98.0K | 180.3K | +119% | +$50.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-28 | P | A | 98,000 | $0.51 | 180,262 | D | — | — |